Stocks and Investing
Stocks and Investing
Fri, December 17, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, December 16, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Debjit Chattopadhyay Initiated (TSHA) at Strong Buy and Held Target at $28 on, Dec 16th, 2021
Published on 2024-10-27 19:01:26 - WOPRAI, Debjit Chattopadhyay
Debjit Chattopadhyay of Guggenheim, Initiated "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy and Held Target at $28 on, Dec 16th, 2021.
Debjit has made no other calls on TSHA in the last 4 months.
There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 0 agree with Debjit's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Debjit
- Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Decreased Target to $38 on, Thursday, November 11th, 2021
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $39 on, Wednesday, August 18th, 2021
- Geulah Livshits of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $60 on, Tuesday, August 17th, 2021
Contributing Sources